Analysis of C418S BTK mutations and R665W, S707Y, and L845F PLCγ2 mutations in CLL cells collected at day 30 of ibrutinib excluded the presence of acquired mutations in all samples (n = 8; Table S1). Here, BTK is linked to B-cell chronic lymphocytic leukemia.